Pfizer’s COVID-19 booster shot for U.S. kids ages 5 to 11 has been approved by the FDA. Next, it will need the CDC’s final sign-off.
, and the FDA is expected to evaluate data from one or both companies sometime next month.
But in a small study, Pfizer found a booster revved up those kids’ levels of virus-fighting antibodies — including those able to fight omicron — the same kind of jump adults get from an extra shot. Vaccination may not always prevent milder infections, especially as omicron and other strains are better than some prior variants at slipping past those defenses. But health authorities agree that vaccinations continue to offer strong protection against the worst outcomes of COVID-19, including hospitalization and death.
Australia Latest News, Australia Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
FDA authorizes Pfizer COVID-19 booster shots for children ages 5 to 11The FDA has granted emergency use authorization for a booster dose of Pfizer/BioNTech's COVID-19 vaccine for children ages 5 to 11 at least five months after completion of the primary vaccine series.
Read more »
FDA authorizes Pfizer Covid booster for children 5 to 11 years oldA study in February found that two doses of the vaccine offered little protection against the omicron variant.
Read more »
FDA Authorizes Pfizer Covid Booster Dose for Kids Ages 5 to 11 Years OldThe Food and Drug Administration on Tuesday authorized a Pfizer booster dose for children ages 5 through 11 years old at least five months after they complete their two-dose primary series. Dr. Peter Marks, head of the FDA division responsible for vaccines, said data increasingly shows that the protection provided by two shots wanes off over time. The FDA determined…
Read more »
FDA authorizes first non-prescription test for COVID-19, flu, RSVNEW: The FDA has authorized the first non-prescription COVID-19 test that can also detect the flu and RSV.
Read more »
FDA Authorizes Nonprescription Test for Covid-19, Flu and RSVThe FDA authorized the first nonprescription test for Covid-19, influenza and RSV, in another step toward increasing patient access to tests for Covid-19 and other conditions
Read more »
FDA: fluvoxamine doesn’t treat COVID-19 — and here’s 27 pages whyThat transparency isn’t normal.
Read more »